Polaris Partners Files for New $400 Million Fund

June 18, 2019

Boston based life science and tech VC, Polaris Partners has filed the paperwork for a new $400 million fund. The company has yet to raise money for the fund.

While Polaris has not commented on the business focus of the fund, the company invests in the life science and tech arenas. Polaris has invested in over 100 life science related companies and its porfolio includes; Alnylam Pharmaceuticals, Alimera Sciences, Ironwood, Ocular Therapeutix, etc.

Polaris made more than $200 million in VC deals last year. The company has offices in Boston, New York and San Francisco.

Tags:
Polaris Partners
Subscribe to our newsletter and receive articles like this and our industry news headlines in your email
admin

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

Latest CP Wire Articles

PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies
Sapio Sciences launches new drug discovery platform
Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
Why Medical and Pharma Sales Reps Should Start Their Own Senior Care Business
Bend Bioscience Adds Capacity and Technology Offerings with the Addition of New Process and Manufacturing Science Facility
Eastman introduces new excipient to formulate poorly soluble API

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.

Do Not Allow Advertisers to Use My Personal information